The synergistic effect of the PARP inhibitor and of platinum-based chemotherapy was assessed in a randomized phase 2 study including treatment-naive patients with pancreatic cancer with germline BRCA1/2 or PALB2 mutations. The gene discussed is BRCA1; the disease is familial pancreatic carcinoma.